Warfarin dosing and cytochrome P450 2C9 polymorphisms

Summary

Two cytochrome P450 2C9 (CYP2C9) polymorphisms, CYP2C9*2 and *3, metabolize warfarin inefficiently. We assessed the extent to which these polymorphisms explain very low warfarin dose requirements and hemorrhagic complications after excluding non-genetic determinants of warfarin dosing. In this retrospective observational study, 73 patients with stable warfarin doses for ≥1 month and International Normalized Ratios (INR) of 2.0–3.0 were enrolled from our Anticoagulation Clinic. Seventeen patients required ≤2 mg (low-dose), 41 required 4–6 mg (moderate-dose), and 15 required ≥10 mg (high-dose) of daily warfarin. CYP2C9 genotyping was assessed by PCR amplification and restriction enzyme digestion analysis of DNA isolated from circulating leukocytes. The CYP2C9 polymorphisms independently predicted low warfarin requirements after adjusting for Body Mass Index, age, acetaminophen use, and race (OR 24.80; 95% CI 3.83–160.78). At least one polymorphism was present in every patient requiring ≤1.5 mg of daily warfarin, and 88%, 37%, and 7% of the low-, moderate-, and high-dose groups, respectively. All homozygotes and compound-heterozygotes for the variant alleles were in the low-dose group. Rates of excessive (INR>6.0) anticoagulation (and bleeding) were 4.5 (6.0), 7.9 (7.9), and 14.7 (0) per 100 patient-years in the wild-types, heterozygotes, and compound heterozygotes/homozygotes, respectively. In conclusion, CYP2C9*2 or *3 compound heterozygotes and homozygotes have low warfarin requirements even after excluding liver disease, excessive alcohol or acetaminophen consumption, low body weight, advancing age, and drug interactions. These polymorphisms increase the rate of excessive anticoagulation, but this risk does not appear to be associated with higher bleeding rates when anticoagulation status is closely monitored.

Keywords

Anticoagulants - metabolism - genetics - hemorrhage

^* Both authors contributed equally to this work

• References

• 1 Hirsh J, Dalen DE, Anderson DR. et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001; 119: 8S-21S.
• 2 James AH, Britt RP, Raskino CL. et al. Factors affecting the maintenance dose of warfarin. J Clin Pathol 1992; 45: 704-6.
• 3 Hallak HO, Wedlund PJ, Modi MW. et al. High clearance of (S)-warfarin in a warfarinresistant subject. Br J Clin Pharmacol 1993; 35: 327-30.
• 4 Taube J, Halsall D, Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 2000; 96: 1816-9.
• 5 Physicians’ Desk Reference. Montvale: Medical Economics Company Inc; 2002
• 6 Wells PS, Holbrook AM, Crowther NR. et al. Interactions of warfarin with drugs and food. Ann Intern Med 1994; 121: 676-83.
• 7 Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 2002; 12: 251-63.
• 8 Stubbins MJ, Harries LW, Smith G. et al. Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics 1996; 06: 429-39.
• 9 Rettie AE, Haining RL, Bajpai M. et al. A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin. Epilepsy Res 1999; 35: 253-5.
• 10 Yamazaki H, Inoue K, Chiba K. et al. Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leuvariants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes. Biochem Pharmacol 1998; 56: 243-51.
• 11 Bhasker CR, Miners JO, Coulter S. et al. Allelic and functional variability of cytochrome P4502C9. Pharmacogenetics 1997; 07: 51-8.
• 12 Aithal GP, Day CP, Kesteven PJL. et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353: 717-9.
• 13 Joffe HV, Goldhaber SZ. Effectiveness and safety of long-term anticoagulation of patients ≥90 years of age with atrial fibrillation. Am J Cardiol 2002; 90: 1397-8.
• 14 Gurwitz JH, Avorn J, Ross-Degnan D. et al. Aging and the anticoagulant response to warfarin therapy. Ann Intern Med 1992; 116: 901-4.
• 15 Hylek EM, Heiman H, Skates SJ. et al. Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA 1998; 279: 657-62.
• 16 Sullivan-Klose TH, Ghanayem BI, Bell DA. et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996; 06: 341-9.
• 17 Yasar U, Eliasson E, Dahl ML. et al. Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun 1999; 254: 628-31.
• 18 Higashi MK, Veenstra DL, Kondo LM. et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002; 287: 1690-8.
• 19 Harrison L, Johnston M, Massicotte MP. et al. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med 1997; 126: 133-6.
• 20 Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med 1998; 158: 1641-7.
• 21 Thijssen HHW. Vitamin K epoxide reductase of Scottish resistance genes is not irreversibly blocked by warfarin. Biochem Pharmacol 1987; 36: 2753-7.
• 22 Linder MW. Genetic mechanisms for hypersensitivity and resistance to the anticoagulant warfarin. Clinica Chimica Acta 2001; 308: 9-15.
• 23 Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med 1993; 95: 315-28.